日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Letter to the Editor Regarding "Dupilumab Versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo Adjusted Indirect Treatment Comparison"

致编辑的信，主题为“使用安慰剂调整的间接治疗比较，Dupilumab 与 Lebrikizumab 相比，更有可能实现并维持疗效结果的改善”

期刊:Dermatology and Therapy
影响因子:4.2
doi:10.1007/s13555-025-01622-9
Chovatiya, Raj; Seminario-Vidal, Lucia; Gallo, Gaia; Ding, Yuxin; Yang, Chao; Akmaz, Bülent; Solé-Feu, Laia; Rand, Kim
发表日期：2026
文献求助 收藏

What do HTA agencies need for generating health-related quality of life evidence? Findings from a global survey

卫生技术评估机构需要哪些信息来生成与健康相关的生活质量证据？一项全球调查的结果

期刊:International Journal of Technology Assessment in Health Care
影响因子:
doi:10.1017/S0266462326103602
Vasan Thakumar, Annushiah; Lorgelly, Paula; Longworth, Louise; Rey-Ares, Lucila; Purba, Fredrick; Golicki, Dominik; Augustovski, Federico; Rand, Kim; Viney, Rosalie; Bansback, Nick; Luo, Nan
发表日期：2026
文献求助 收藏

Health-related quality of life and QALY loss under COVID-19 lockdown: The case of Spain

新冠疫情封锁期间的健康相关生活质量和质量调整生命年损失：以西班牙为例

期刊:PLoS One
影响因子:2.6
doi:10.1371/journal.pone.0329413
Janssen, Mathieu F; Rand, Kim; Estévez-Carrillo, Anabel; Ramos-Goñi, Juan Manuel
微生物学
新冠
发表日期：2025
文献求助 收藏

Cost Effectiveness of Sequencing Vedolizumab as First-Line Biologic in Ulcerative Colitis and Crohn's Disease in Canada: An Analysis Using Real-World Evidence from the EVOLVE Study

在加拿大，维多珠单抗作为溃疡性结肠炎和克罗恩病一线生物制剂的序贯治疗的成本效益分析：基于EVOLVE研究真实世界证据的分析

期刊:Pharmacoeconomics-Open
影响因子:2.1
doi:10.1007/s41669-024-00523-5
Fischer, Aren; Mac, Stephen; Freiman, Erica Stivelman; Marshall, John K; Rand, Kim; Ramos-Goñi, Juan M
结肠炎
克罗恩病
肠炎
发表日期：2025
文献求助 收藏

Developing an EQ-5D-5L Value Set for Singapore

为新加坡制定 EQ-5D-5L 价值观体系

期刊:Pharmacoeconomics
影响因子:
doi:10.1007/s40273-025-01519-7
Luo, Nan; Vasan Thakumar, Annushiah; Cheng, Ling Jie; Yang, Zhihao; Rand, Kim; Cheung, Yin Bun; Thumboo, Julian
发表日期：2025
文献求助 收藏

Is episodic future thinking effective in mitigating the influence of time preference in time trade-off?

情景式未来思维能否有效减轻时间偏好对时间权衡的影响？

期刊:European Journal of Health Economics
影响因子:
doi:10.1007/s10198-025-01812-4
Lang, Zhongyu; Zhang, Liying; Lipman, Stefan A; Sugden, Bradley; Rand, Kim; Attema, Arthur E
发表日期：2025
文献求助 收藏

Correction: Is episodic future thinking effective in mitigating the influence of time preference in time trade-off?

更正：情景式未来思维能否有效减轻时间偏好在时间权衡中的影响？

期刊:European Journal of Health Economics
影响因子:
doi:10.1007/s10198-025-01862-8
Lang, Zhongyu; Zhang, Liying; Lipman, Stefan A; Sugden, Bradley; Rand, Kim; Attema, Arthur E
发表日期：2025
文献求助 收藏

Correction to: Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab versus Dupilumab in Moderate-to-Severe Atopic Dermatitis

更正：Lebrikizumab 与 Dupilumab 在中重度特应性皮炎中长期疗效维持和不良事件发生率的匹配调整间接比较

期刊:Dermatology and Therapy
影响因子:4.2
doi:10.1007/s13555-023-01076-x
Rand, Kim; Ramos-Goñi, Juan Manuel; Akmaz, Bülent; Solé-Feu, Laia; Armario-Hita, José-Carlos
发表日期：2024
文献求助 收藏

Response to "Letter to the Editor Regarding 'Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab vs. Dupilumab in Moderate to Severe Atopic Dermatitis'"

对“致编辑的信，内容涉及‘Lebrikizumab 与 Dupilumab 在中重度特应性皮炎中的长期疗效维持率和不良事件发生率的匹配调整间接比较’”的回应

期刊:Dermatology and Therapy
影响因子:4.2
doi:10.1007/s13555-024-01107-1
Rand, Kim; Ramos-Goñi, Juan Manuel; Akmaz, Bülent; Solé-Feu, Laia; Armario-Hita, José-Carlos
发表日期：2024
文献求助 收藏

Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab versus Dupilumab in Moderate-to-Severe Atopic Dermatitis

匹配调整间接比较Lebrikizumab与Dupilumab治疗中重度特应性皮炎的长期疗效维持率和不良事件发生率

期刊:Dermatology and Therapy
影响因子:4.2
doi:10.1007/s13555-023-01058-z
Rand, Kim; Ramos-Goñi, Juan Manuel; Akmaz, Bülent; Solé-Feu, Laia; Armario-Hita, José-Carlos
发表日期：2024
文献求助 收藏